Abstract
Pulmonary arterial hypertension (PAH) is characterized by the excessive proliferation of pulmonary arterial smooth muscle cells (PASMCs), leading to vascular remodeling and right heart failure. Recent research highlights the role of mitochondrial dysfunction and calcium (Ca²⁺) signaling imbalances in driving this pro-proliferative state. Central to this process is the Mitochondria-Associated Membrane (MAM), where the endoplasmic reticulum (ER) and mitochondria interact to regulate cellular metabolism and ion transport. This study identifies Mitochondrial fusion protein 2 (Mfn2) as a key mediator of mitochondrial Ca²⁺ transport via its interaction with the Type 3 inositol 1,4,5-trisphosphate receptor (IP3R3), providing a theoretical basis for novel PAH therapeutics.
The Mfn2-IP3R3 Axis in Calcium Homeostasis
Mfn2 is traditionally known for its role in mitochondrial fusion, but it also serves as a critical tethering protein at the MAM. Under physiological conditions, Mfn2 interacts with IP3R3 to facilitate the efficient transfer of Ca²⁺ from the ER into the mitochondria. This regulated flow ensures mitochondrial metabolic efficiency and prevents the accumulation of excess Ca²⁺ in the cytoplasm, which would otherwise trigger pathological cell growth.
Pathological Disruption in PAH
In models of PAH—including monocrotaline (MCT)-induced rats and TNF-α-treated PASMCs—Mfn2 expression is significantly downregulated. This loss of Mfn2 disrupts the MAM architecture and leads to the compensatory upregulation of IP3R3 and various ER stress markers, such as CHOP and ATF4. The resulting imbalance causes Ca²⁺ to "leak" into the cytoplasm, promoting the rapid proliferation of PASMCs. Simultaneously, the mitochondria are starved of Ca²⁺, leading to structural damage, impaired cristae formation, and the induction of autophagy.
Therapeutic Intervention and Results
The study demonstrated that restoring the Mfn2-IP3R3 axis can mitigate PAH progression. Genetic overexpression of Mfn2 or pharmacological inhibition of IP3R3 successfully normalized cellular Ca²⁺ levels and inhibited PASMC proliferation. Furthermore, treatment with the ER stress inhibitor 4-phenylbutyric acid (4-PBA) and cistanche phenylethanol glycosides (CPGs)—a traditional Chinese medicine extract—showed significant hemodynamic improvements. In PAH rats, these treatments lowered mean pulmonary arterial pressure (mPAP) from approximately 50 mmHg toward the normal range (16-22 mmHg) and significantly reduced vascular wall thickness.
Conclusion
The interaction between Mfn2 and IP3R3 at the MAM is a vital regulator of vascular health. By maintaining calcium homeostasis and suppressing the pro-proliferative phenotype of PASMCs, this axis presents a promising target for future PAH therapies. The efficacy of CPGs in this pathway further validates the potential of integrating traditional medicinal extracts into modern molecular treatments for vascular remodeling.
Summary updated